The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia

Basit Öğe Kaydı
dc.contributor.authorAksu, Salih
dc.contributor.authorSahin, Fahri
dc.contributor.authorUz, Burak
dc.contributor.authorYavuz, Selim A.
dc.contributor.authorAtay, Hilmi
dc.contributor.authorKelkitli, Engin
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorAkay, Meltem O.
dc.contributor.authorGuray, Emel
dc.contributor.authorDemir, Muzaffer
dc.contributor.authorKahraman, Selda
dc.contributor.authorDemirkan, Fatih
dc.contributor.authorPaydas, Semra
dc.contributor.authorSaydam, Güray
dc.contributor.authorHaznedaroglu, Ibrahim C.
dc.date.accessioned2019-10-27T21:34:01Z
dc.date.available2019-10-27T21:34:01Z
dc.date.issued2012
dc.departmentEge Üniversitesien_US
dc.description.abstractWe report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.en_US
dc.identifier.doi10.4999/uhod.12004
dc.identifier.endpage14en_US
dc.identifier.issn1306-133X
dc.identifier.issn1306-133Xen_US
dc.identifier.issue1en_US
dc.identifier.startpage8en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.12004
dc.identifier.urihttps://hdl.handle.net/11454/45522
dc.identifier.volume22en_US
dc.identifier.wosWOS:000306389200002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic myeloid leukemiaen_US
dc.subjectDasatiniben_US
dc.subjectTreatment dosageen_US
dc.titleThe Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu